To date, the aberrant overexpression of MUC4 has been reported in pancreatic malignancies, but not in the normal pancreas, which has made MUC4 a promising therapeutic target for anti-cancer adjuvant therapies (Andrianifahanana et al, 2001). Here, MUC4 is linked to cancer.